Plain-English translation of NCT06301373 on ClinicalTrials.gov ↗ · Source last updated ·
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial is testing whether adding tofacitinib to works better than alone for people with a specific, harder-to-treat type of rheumatoid arthritis. Researchers have found that some people with rheumatoid arthritis have a particular pattern of inflammation that doesn't respond as well to standard single-drug treatment. This study wants to see if combining the medication with another drug called tofacitinib can improve outcomes for these patients.
About half of rheumatoid arthritis patients don't improve enough with alone in the first three months, and many require additional treatment. This medication has shown promise in other situations, but doctors need to know if starting it earlier—alongside —can help people with this specific type of arthritis avoid joint damage and disability.
You likely qualify if…
You likely don't qualify if…
You will be randomly assigned to take either alone or . Both are oral medications taken at home— once a week, and tofacitinib twice daily (if in the combination group). You will have regular clinic visits to monitor how well the treatment is working and check for any side effects. The trial will track your joint symptoms, inflammation levels, and any changes in your condition over time.
AI-generated summary from trial data · Jun 5, 2026 · Not medical advice
China